SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).

Lupus Awareness Month occurs every May and is an opportunity for lupus-focused organizations to take intentional steps in creating awareness around lupus and those impacted. Lupus is a disease that AVISE^® testing is specially equipped to help with and today marks the start of a month-long campaign around Bringing Awareness to Lupus Symptoms.

To deliver on this campaign, Exagen will be focusing on:

1. A partnership with Lupus Foundation of America, providing patient educational materials to rheumatologists that showcase the importance of identifying common signs of lupus, getting a diagnosis and resources for help.
2. Patient advocates sharing their personal journey to diagnosis and the impact of repeat testing and multiple doctor visits.
3. Educational content shared through multiple mediums to bring awareness to lupus symptoms and its effect on the body.

This campaign will run from May 1^st through the end of the month.

“Receiving a diagnosis is a central part of the journey for patients dealing with autoimmune diseases. Our mission is to shorten the time to diagnosis, empowering providers and their patients to change the trajectory of their health, especially for those dealing with lupus. Spreading awareness is key and we are proud to work with our partners to cultivate that awareness,” said John Aballi, President and CEO of Exagen.

Interested in learning more? Visit AviseTest.com/patient for helpful resources or follow Exagen social media platforms here: Facebook, LinkedIn, Twitter.

About Exagen Inc.

Exagen is a leading provider of autoimmune diagnostic, prognostic and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE^® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians and payors by enabling precision medicine. Exagen is located in San Diego County.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect its business, financial condition and results of operations, including as a result of slowdown in its operations as well as those of its suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for its tests causing an increase in cost per test, its sales and commercialization activities and its ability to receive specimens and perform or deliver the results from its tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations
Exagen Inc.
Ryan Douglas
This email address is being protected from spambots. You need JavaScript enabled to view it. 
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.